Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With
Publication Title
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Document Type
Article
Publication Date
5-15-2024
Keywords
oregon; portland
Abstract
PURPOSE: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with biliary tract cancer (BTC) with
METHODS: Eligible patients had advanced BTC, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with
RESULTS: Twenty-nine patients were enrolled from February 2017 to January 2022, and all had advanced BTC with an
CONCLUSION: Pertuzumab plus trastuzumab met prespecified criteria to declare a signal of activity in patients with BTC and
Clinical Institute
Cancer
Clinical Institute
Digestive Health
Specialty
Oncology
Specialty
Gastroenterology
Specialty
Surgery
Recommended Citation
Cannon, Timothy L; Rothe, Michael; Mangat, Pam K; Garrett-Mayer, Elizabeth; Chiu, Vi K; Hwang, Jimmy; Vijayvergia, Namrata; Alese, Olatunji B; Dib, Elie G; Duvivier, Herbert L; Klute, Kelsey A; Sahai, Vaibhav; Ahn, Eugene R; Bedano, Pablo; Behl, Deepti; Sinclair, Sarah; Thota, Ramya; Urba, Walter; Yang, Eddy S; Grantham, Gina N; Hinshaw, Dominique C; Gregory, Abigail; Halabi, Susan; and Schilsky, Richard L, "Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With" (2024). Articles, Abstracts, and Reports. 8864.
https://digitalcommons.providence.org/publications/8864
